• Imagine being able to respond to a new influenza strain within the same flu season
    with a painless and room temperature stable vaccine

Read More

  • The CDC recommends over 40 vaccinations for a child by age 6.
    Imagine sparing the children over 30 needles
Vaccine Vision

A broad family of room temperature stable vaccines self administered via a painless patch...

read more
Featured Article
U.S. Travelers Skip Measles Vaccines, Study Finds More than half of U.S. adults who should get vaccinated against measles before traveling abroad don’t do it, a new study suggests. The U.S. Centers for Disease Control and Prevention recommends two doses of the measles, mumps and rubella (MMR) vaccine for adults traveling outside the U.S. who were born before 1957 and lack either a documented measles infection, records of adequate vaccination or a positive blood test for immunity to measles. ...
read more
Featured Team Member

Dr. D. R. Henderson
Chief Executive Officer

Dan has experience and success in founding and building biopharmaceutical companies. He holds a Ph.D. in Medical Sciences from the University of New Mexico School of Medicine and was a postdoctoral scholar at Duke University Medical Center. He founded Microgenics Corporation. At Microgenics, Dan invented the CEDIA™ immunoassay system used in clinical laboratories throughout the world. CEDIA™ immunoassays now sell over $1B annually: please see www.usdiagnostics.roche.com and then search for CEDIA™ on their website; repeat at www.thermofisher.com. For this work, the American Association for Clinical Chemistry (AACC) awarded the 2015 biennial Ullman Prize for Technology Innovation to Dr. Henderson.

Dan also founded Calydon where he genetically engineered adenovirus targeting prostate cancer. For this work he was recognized as one of the two pioneers in the field of oncolytic virotherapy (Scientific American, “Tumor Busting Viruses”, October 2003). Calydon was sold to Cell Genesys. 2015 saw the first FDA approved oncolytic virus, a herpesvirus for melanoma.

Dr. Henderson also co-founded PaxVax, a manufacturer and developer of vaccines for travelers to countries without adequate water sanitation (Typhoid, Cholera and Hepatitis A) and the U.S. Military (Anthrax) (see www.paxvax.com). PaxVax was named Best Early-Stage Vaccine Biotech company at the 16th annual World Vaccine Congress in Washington, D.C., March, 2016 and received FDA approval for a Single Dose Oral Cholera vaccine in June. Dan holds 34 issued US Patents.

read more